Pulvirenti L, Koob G F
Department of Biology, University of Rome, Tor Vergata, Rome, Italy.
Trends Pharmacol Sci. 1994 Oct;15(10):374-9. doi: 10.1016/0165-6147(94)90158-9.
Despite the epidemic growth of psychostimulant addiction over the past years, few pharmacological means of intervention are available to date for clinical treatment. This is of importance since the withdrawal syndrome that follows abstinence from drugs such as cocaine and the amphetamines is characterized, among other symptoms, by intense craving for the abused drug, and this is considered a critical factor leading into relapse of drug use. In this article, Luigi Pulvirenti and George Koob focus on the modulatory role shown by drugs acting at the dopamine receptor on the various phases of psychostimulant dependence in preclinical models and in human studies, and suggest that a class of compounds with partial agonist properties at the dopamine receptor may have therapeutic potential.
尽管在过去几年中精神刺激药物成瘾呈流行式增长，但迄今为止，临床上可用的药物干预手段却很少。这一点很重要，因为诸如可卡因和安非他命等药物戒断后的戒断综合征，除其他症状外，其特征还包括对滥用药物的强烈渴望，而这被认为是导致药物使用复发的关键因素。在本文中，路易吉·普尔维伦蒂和乔治·库布着重探讨了作用于多巴胺受体的药物在临床前模型和人体研究中对精神刺激药物依赖各个阶段所表现出的调节作用，并提出一类在多巴胺受体上具有部分激动剂特性的化合物可能具有治疗潜力。
